Literature DB >> 32582520

Four cases of Trousseau syndrome associated with breast cancer that exhibited central nervous system manifestations.

Mai Okazaki1,2, Hiroko Bando3, Emika Ichioka3, Akiko Iguchi-Manaka3, Katsuhiro Nasu4, Hisato Hara3.   

Abstract

Cancer-associated thrombosis is known as Trousseau syndrome (TS). Here, we report 4 cases of TS associated with advanced breast cancer that caused central nervous system (CNS) vascular events. All 4 patients experienced sudden onset of CNS symptoms. Imaging revealed multiple brain infarctions or intracranial hemorrhage and all 4 patients had leptomeningeal or brain metastasis. Laboratory findings showed hypercoagulability at diagnosis of TS. Of the 4 patients, 2 patients were treated with unfractionated heparin, while 2 patients could not undergo anticoagulant therapy. In all patients, once the TS occurred, the CNS symptoms progressed rapidly and the prognosis was very poor, 3 patients dying within about a month of diagnosis of TS. Therefore, the predictive factors of TS are important and standards and guidelines for administration of anticoagulants are needed. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Breast cancer; Trousseau syndrome; Venous thromboembolism

Year:  2020        PMID: 32582520      PMCID: PMC7297874          DOI: 10.1007/s13691-020-00411-9

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  11 in total

Review 1.  Trousseau's syndrome: multiple definitions and multiple mechanisms.

Authors:  Ajit Varki
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

Review 2.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Gary H Lyman; Kari Bohlke; Anna Falanga
Journal:  J Oncol Pract       Date:  2015-04-14       Impact factor: 3.840

3.  Tumors, mucus production, and hypercoagulability.

Authors:  G F Pineo; M C Brain; A S Gallus; J Hirsh; M W Hatton; E Regoeczi
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

4.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

5.  Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.

Authors:  Mark Wahrenbrock; Lubor Borsig; Dzung Le; Nissi Varki; Ajit Varki
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

6.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Authors:  Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

Review 7.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Authors:  D Farge; P Debourdeau; M Beckers; C Baglin; R M Bauersachs; B Brenner; D Brilhante; A Falanga; G T Gerotzafias; N Haim; A K Kakkar; A A Khorana; R Lecumberri; M Mandala; M Marty; M Monreal; S A Mousa; S Noble; I Pabinger; P Prandoni; M H Prins; M H Qari; M B Streiff; K Syrigos; H Bounameaux; H R Büller
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

8.  Case series of cerebral infarction with Trousseau's syndrome associated with malignant gynecological tumors.

Authors:  Masako Ishikawa; Kentaro Nakayama; Tomoka Ishibashi; Emi Sato; Kohei Nakamura; Hiroshi Katagiri; Satoru Kyo
Journal:  Mol Clin Oncol       Date:  2016-05-06

Review 9.  Trousseau's syndrome: cancer-associated thrombosis.

Authors:  Soichiro Ikushima; Ryu Ono; Kensuke Fukuda; Masashi Sakayori; Nobuyasu Awano; Keisuke Kondo
Journal:  Jpn J Clin Oncol       Date:  2015-11-06       Impact factor: 3.019

10.  Cancer-associated thrombosis: prevention and treatment.

Authors:  K M J Brose; A Y Y Lee
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.